Trending...
- Some Music for Donald's Bad Day
- Hiclean Tools Releases HCX2100 Electric Pressure Washer
- Thousands to Ride to L.A. Children's Hospital This Halloween Night
CLEVELAND, Jan. 12, 2022 /PRNewswire/ -- GenomOncology announced today that GenomOncology (GO) Pathology Workbench has been selected by Labcorp's OmniSeq to support the analysis and reporting of OmniSeq INSIGHT℠, a comprehensive genomic and immune profiling test for solid tumors.
OmniSeq INSIGHT combines genomic and immune profiling to comprehensively characterize a patient's tumor to identify potential treatment and clinical trial options. OmniSeq INSIGHT examines the full coding region of 523 genes by next generation sequencing for mutations, copy number alterations, fusions microsatellite instability (MSI), tumor mutation burden (TMB), and expression of 64 immune genes in the tumor microenvironment. The test also includes PD-L1 by immunohistochemistry.
"Our partnership with GenomOncology has advanced our ability to efficiently classify variants, match therapies and identify trials located within 200 miles of the patient's home," says Shengle Zhang, MD, Laboratory Director of OmniSeq. "This highly customized laboratory information system supports OmniSeq's competitive turnaround time of matched precision medicine options to ordering clinicians for their cancer patients."
More on Ohio Pen
To streamline variant review, interpretation, and case reporting, OmniSeq implemented the highly customized GO Pathology Workbench. Central to the GO Pathology Workbench's function is a proprietary, algorithmically-driven database of evidence and guideline-based therapeutic options and clinical trials. The results are displayed in the comprehensive OmniSeq INSIGHT test report.
"The adaptability and versatility of the GO Pathology Workbench enabled us to efficiently customize the workbench to accommodate the unique features of the OmniSeq INSIGHT test. By providing the knowledge and evidence needed for effective variant interpretation, GO Pathology Workbench provides a tool to support OmniSeq INSIGHT's swift turnaround time," said Matt Stachowiak, PhD, Director of Product Management at GenomOncology.
In June 2021, Labcorp (NYSE: LH), a leading global life sciences company, acquired OmniSeq. OmniSeq INSIGHT is available to U.S.-based clinicians exclusively through Labcorp, and across Canada through Dynacare, a Labcorp company. The test is also available to global biopharmaceutical companies exclusively through Labcorp Drug Development. For more information about OmniSeq INSIGHT, visit oncology.labcorp.com/omniseq.
More on Ohio Pen
About GenomOncology
GenomOncology provides the healthcare community with data-driven insights to improve cancer care. GenomOncology strengthens your precision oncology program by transforming valuable, but unusable data, into actionable oncology treatment options and strategic insights. GenomOncology's Precision Oncology Platform (POP) powers its comprehensive set of end-to-end software solutions that enhance decision support. POP combines both proprietary content and public and licensed data sets with your internal patient data to provide you the information necessary to improve patient outcomes. Learn more at www.genomoncology.com.
Media Contact
Alysia Kaplan, Director of Marketing
GenomOncology, LLC
(440) 617-6087
[email protected]
SOURCE GenomOncology
OmniSeq INSIGHT combines genomic and immune profiling to comprehensively characterize a patient's tumor to identify potential treatment and clinical trial options. OmniSeq INSIGHT examines the full coding region of 523 genes by next generation sequencing for mutations, copy number alterations, fusions microsatellite instability (MSI), tumor mutation burden (TMB), and expression of 64 immune genes in the tumor microenvironment. The test also includes PD-L1 by immunohistochemistry.
"Our partnership with GenomOncology has advanced our ability to efficiently classify variants, match therapies and identify trials located within 200 miles of the patient's home," says Shengle Zhang, MD, Laboratory Director of OmniSeq. "This highly customized laboratory information system supports OmniSeq's competitive turnaround time of matched precision medicine options to ordering clinicians for their cancer patients."
More on Ohio Pen
- Tobu Railway Group Will Host the Fourth Annual "Take-Akari" Bamboo Lantern Festival in East Tokyo, November 7, 2025 – January 31, 2026
- New Article by Roy J. Meidinger – Examines Hidden Hidden Healthcare Kickbacks
- Why Generic Platforms Fail in Emerging Markets: Bettorify Exposes the Gap Between Promise and Reality
- Blogging Pioneer Sherry Bennett Celebrates 29 Years Online - Sharing the Secrets Behind Her 7-Figure Blog Empire
- Koplon Dentistry Elevates Implant Expertise with Advanced CE Course
To streamline variant review, interpretation, and case reporting, OmniSeq implemented the highly customized GO Pathology Workbench. Central to the GO Pathology Workbench's function is a proprietary, algorithmically-driven database of evidence and guideline-based therapeutic options and clinical trials. The results are displayed in the comprehensive OmniSeq INSIGHT test report.
"The adaptability and versatility of the GO Pathology Workbench enabled us to efficiently customize the workbench to accommodate the unique features of the OmniSeq INSIGHT test. By providing the knowledge and evidence needed for effective variant interpretation, GO Pathology Workbench provides a tool to support OmniSeq INSIGHT's swift turnaround time," said Matt Stachowiak, PhD, Director of Product Management at GenomOncology.
In June 2021, Labcorp (NYSE: LH), a leading global life sciences company, acquired OmniSeq. OmniSeq INSIGHT is available to U.S.-based clinicians exclusively through Labcorp, and across Canada through Dynacare, a Labcorp company. The test is also available to global biopharmaceutical companies exclusively through Labcorp Drug Development. For more information about OmniSeq INSIGHT, visit oncology.labcorp.com/omniseq.
More on Ohio Pen
- i2 Group Acquisitions and Investments in Innovations Deliver 40% Increase in Year-on-Year Bookings
- New Book Release: The Tree That Could Not Change
- BayWa r.e. Solar Trade and WHES Announce Distribution Partnership for the European Market: Delivering Smarter Energy Storage
- Fleet Mining Cloud Mining Platform — Latest Guide: Making Bitcoin Mining Safer and More Convenient
- Keebos Launches Crossbody Cases for Every iPhone 17 Model
About GenomOncology
GenomOncology provides the healthcare community with data-driven insights to improve cancer care. GenomOncology strengthens your precision oncology program by transforming valuable, but unusable data, into actionable oncology treatment options and strategic insights. GenomOncology's Precision Oncology Platform (POP) powers its comprehensive set of end-to-end software solutions that enhance decision support. POP combines both proprietary content and public and licensed data sets with your internal patient data to provide you the information necessary to improve patient outcomes. Learn more at www.genomoncology.com.
Media Contact
Alysia Kaplan, Director of Marketing
GenomOncology, LLC
(440) 617-6087
[email protected]
SOURCE GenomOncology
Filed Under: Business
0 Comments
Latest on Ohio Pen
- Institute for Pet Health Sciences Names Boops Pets 2025 Product of the Year
- Matthew Cossolotto, Author of The Joy of Public Speaking, Appears on "Get Authentic with Marques Ogden" and "Achieving Success with Olivia Atkin"
- CCHR Exposes Conflicted Psychiatrists Behind Teen Antidepressant Surge
- Bruce C. Barnes Joins Summit's Board of Advisors
- WIBO Announces Fall 2025 Entrepreneurship Programs to Empower NYC Founders and Small Business Owners
- Local College Student Launches "Cleopatra" App to Make Cleaning Easy for Mercer County Residents
- Wohler announces release of additional Balance Control output tracking for its eSeries in-rack monitor range
- A Milestone of Giving: Ten Percent Group Donates £25,000 to Cure Parkinson's
- Tami Goveia Enters FabOver40, Inspiring Hollywood Legacy for Breast Cancer Cause
- Swidget Launches Luminance™ to Help Schools Achieve Alyssa's Law Compliance
- Growing Demand for EVA Mats Signals Shift in Car Interior Market
- MDRN MUSE Expands Insurance Network Coverage to Include Delta Dental & Cigna
- Hollywood In Pixels Celebrates the 8th Annual Silver Pixel Awards and Announces 2025 Campaign Pixel Winners Los Angeles, CA — Oct
- Physician Calls for States Nationwide to Ensure ADA Compliance in Independent Commissions
- MEDIA ADVISORY - Strengthening Children's Mental Health Across New Jersey
- NumberSquad Launches Year‑Round Tax Planning Package for Small Businesses and the Self‑Employed
- GlexScale launches a unified model for sustainable SaaS expansion across EMEA
- SwagHer Society Launches to Help Black Women Be Seen and Supported
- Why Philadelphia Homeowners Should Ditch Oil for Natural Gas
- Zero-Trust Architecture: NJTRX Addresses 60% of U.S. Investors' Custody Security Concerns